2025 France Antibodies In Oncology Market Revenue Opportunities Report
Description
The 2025 France Antibodies In Oncology Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies in Oncology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antibodies in oncology market in France include Sanofi, Novartis, OSE Immunotherapeutics, and Nanobiotix. Sanofi, headquartered in France, focuses significantly on molecular oncology and immuno-oncology, investing in new cancer drug technologies and genomic medicine platforms. Novartis, a global leader with important operations in France, is heavily engaged in oncology including antibody-based therapies, developing bispecific antibodies and acquiring companies to boost their oncology pipeline, having recently acquired MorphoSys and Mariana Oncology to strengthen their antibody programs. OSE Immunotherapeutics develops first-in-class immunotherapies, including monoclonal antibodies like Tedopi in advanced clinical trials for non-small cell lung cancer and pancreatic cancer, and collaborates with Boehringer Ingelheim on SIRPα inhibitors for head and neck cancer. Nanobiotix specializes in nanoparticle-based radioenhancers that augment cancer radiotherapy, with major collaborations such as with Johnson & Johnson’s Janssen for head and neck cancers, contributing innovative antibody-related therapies in oncology.
These companies combine strong local R&D with international partnerships, making France an active hub for antibody drug development in oncology. They contribute to France’s large biotech ecosystem, where oncology is the leading therapeutic focus with many biotech firms developing antibody-based treatments. Together, they are advancing monoclonal and bispecific antibody therapies that target various solid tumors and hematologic cancers, supporting France's role in the growing antibody drug market projected to reach USD 685 billion globally by 2034.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies in Oncology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antibodies in oncology market in France include Sanofi, Novartis, OSE Immunotherapeutics, and Nanobiotix. Sanofi, headquartered in France, focuses significantly on molecular oncology and immuno-oncology, investing in new cancer drug technologies and genomic medicine platforms. Novartis, a global leader with important operations in France, is heavily engaged in oncology including antibody-based therapies, developing bispecific antibodies and acquiring companies to boost their oncology pipeline, having recently acquired MorphoSys and Mariana Oncology to strengthen their antibody programs. OSE Immunotherapeutics develops first-in-class immunotherapies, including monoclonal antibodies like Tedopi in advanced clinical trials for non-small cell lung cancer and pancreatic cancer, and collaborates with Boehringer Ingelheim on SIRPα inhibitors for head and neck cancer. Nanobiotix specializes in nanoparticle-based radioenhancers that augment cancer radiotherapy, with major collaborations such as with Johnson & Johnson’s Janssen for head and neck cancers, contributing innovative antibody-related therapies in oncology.
These companies combine strong local R&D with international partnerships, making France an active hub for antibody drug development in oncology. They contribute to France’s large biotech ecosystem, where oncology is the leading therapeutic focus with many biotech firms developing antibody-based treatments. Together, they are advancing monoclonal and bispecific antibody therapies that target various solid tumors and hematologic cancers, supporting France's role in the growing antibody drug market projected to reach USD 685 billion globally by 2034.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
